Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc ADR (GSK)

Glaxosmithkline Plc ADR (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,080,760
  • Shares Outstanding, K 2,692,595
  • Annual Sales, $ 43,783 M
  • Annual Income, $ 7,382 M
  • 60-Month Beta 0.70
  • Price/Sales 2.47
  • Price/Cash Flow 10.36
  • Price/Book 3.67
Trade GSK with:

Options Overview

Details
  • Implied Volatility 17.88%
  • Historical Volatility 14.05%
  • IV Percentile 7%
  • IV Rank 2.92%
  • IV High 47.71% on 01/27/21
  • IV Low 16.98% on 05/03/21
  • Put/Call Vol Ratio 0.26
  • Today's Volume 2,258
  • Volume Avg (30-Day) 3,723
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 175,265
  • Open Int (30-Day) 157,872

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.76
  • Number of Estimates 3
  • High Estimate 0.86
  • Low Estimate 0.61
  • Prior Year 0.92
  • Growth Rate Est. (year over year) -17.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.87 +3.27%
on 07/20/21
40.63 -1.21%
on 07/12/21
+0.32 (+0.80%)
since 06/30/21
3-Month
37.37 +7.41%
on 05/03/21
41.44 -3.14%
on 06/16/21
+2.80 (+7.50%)
since 04/30/21
52-Week
33.26 +20.69%
on 10/30/20
42.40 -5.33%
on 08/12/20
-0.11 (-0.27%)
since 07/30/20

Most Recent Stories

More News
GSK receives authorization under Health Canada's Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents

COMTEX_390677181/2669/2021-07-30T14:34:28

GSK : 40.14 (+0.10%)
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y

Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.

GSK : 40.14 (+0.10%)
RHHBY : 48.2600 (+1.05%)
SGEN : 153.39 (+4.38%)
GMAB : 45.06 (+0.96%)
Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline

Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.

GSK : 40.14 (+0.10%)
MRK : 76.87 (-0.08%)
GILD : 68.29 (-2.21%)
RGEN : 245.70 (+1.95%)
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients

COMTEX_390664251/2669/2021-07-30T10:30:26

GSK : 40.14 (+0.10%)
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV

Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.

SNY : 51.56 (+0.06%)
AZN : 57.24 (-0.69%)
GSK : 40.14 (+0.10%)
PFE : 42.81 (+0.05%)
MRK : 76.87 (-0.08%)
LLY : 243.50 (-0.75%)
ABBV : 116.30 (-2.16%)
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps

GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients...

GSK : 40.14 (+0.10%)
GSK.LN : 1,417.800 (+0.81%)
Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised

Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.

REGN : 574.61 (-1.46%)
SNY : 51.56 (+0.06%)
GSK : 40.14 (+0.10%)
TBIO : 27.64 (-22.38%)
Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track

Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

GSK : 40.14 (+0.10%)
JNJ : 172.20 (+0.01%)
PFE : 42.81 (+0.05%)
VIR : 35.65 (-2.03%)
3 Best Dividend Stocks to Buy with Yields of More Than a 5%

We believe dividend-paying companies with stable fundamentals are prominent bets now considering the market’s high volatility. So, established dividend stocks AT&T Inc. (T), Vale S.A (VALE), and GlaxoSmithKline...

T : 28.05 (-0.85%)
VALE : 21.02 (-8.09%)
GSK : 40.14 (+0.10%)
Glaxo: Q2 Earnings Snapshot

BRENTFORD, Britain (AP) _ GlaxoSmithKline PLC (GSK) on Wednesday reported second-quarter earnings of $1.95 billion.

GSK : 40.14 (+0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

3rd Resistance Point 40.46
2nd Resistance Point 40.31
1st Resistance Point 40.23
Last Price 40.14
1st Support Level 40.00
2nd Support Level 39.85
3rd Support Level 39.77

See More

52-Week High 42.40
Last Price 40.14
Fibonacci 61.8% 38.91
Fibonacci 50% 37.83
Fibonacci 38.2% 36.75
52-Week Low 33.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar